A profile of present trends in bronchogenic carcinoma

---

Author Details : M Kiran, Bhooma Venkata Ramana*, Srinidhi Ramanadham, Harika Potla, Mohana Pradeepika

Volume : 4, Issue : 1, Year : 2019

Article Page : 43-47

https://doi.org/10.18231/2581-4222.2019.0010

Suggest article by email

Get Permission

---

Abstract

Background: Bronchogenic carcinoma is the most common malignancy primarily linked to smoking, pollution and industrial carcinogenic material which enters into human body through inhalation. This malignancy is in uptrend in the last 5 to 7 decades. There are different histological types in lung malignances which responds to different treatment modalities differently.
Methodology: A prospective study of patients in OP and respiratory wards of GGH Kakinada over a period of 18 months between Jan 2017 and July 2018 are taken for the study.
Results: This study comprises of 150 patients out of which males were 121 and females were 29. They are subjected to different kinds of tests and pathological diagnosis are arrived for 125 patients by a battery of tests. 104 were males and 21 were females for which the statistical analysis was made.
Conclusions: The most common histological variant in this study is squamous cell carcinoma followed by adeno carcinoma suggesting that tobacco smoking is an important risk factor for lung cancer even after continuing health awareness and education programs in India. Adeno carcinoma is most common variant among women and nonsmokers.

Keywords: Bronchogenic carcinoma; Bronchoscopy; Squamous cell carcinoma; Targeted therapy.

How to cite : Kiran M, Ramana B V, Ramanadham S, Potla H, Pradeepika M, A profile of present trends in bronchogenic carcinoma. IP Indian J Immunol Respir Med 2019;4(1):43-47

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.